摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(二甲基苯氧基)乙醇 | 54411-20-0

中文名称
2-(二甲基苯氧基)乙醇
中文别名
——
英文名称
2,4-dimethylphenoxyethanol
英文别名
2-<2,4-Dimethyl-phenoxy>-ethanol;2-(2,4-dimethyl-phenoxy)-ethanol;2-(2,4-Dimethyl-phenoxy)-aethanol;4-(β-Oxy-aethoxy)-1.3-dimethyl-benzol;Aethylenglykol-mono-(2.4-dimethyl-phenylaether);Ethanol, 2-(2,4-dimethylphenoxy)-;2-(2,4-dimethylphenoxy)ethanol
2-(二甲基苯氧基)乙醇化学式
CAS
54411-20-0
化学式
C10H14O2
mdl
——
分子量
166.22
InChiKey
DMMLIWIXFIVKFJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    新型 N-[(苯氧基)烷基]-和 N-[(苯氧基)乙氧基乙基]氨基链烷醇的设计、合成和抗惊厥-镇痛活性†‡
    摘要:
    合成了N -[(苯氧基)烷基]-和N -[(苯氧基)乙氧基乙基]氨基烷醇的新衍生物,并评估了它们在最大电休克 (MES)、最大电休克发作阈值 (MEST) 和戊四唑 (PTZ) 中的抗惊厥活性) 测试。通过旋转棒和烟囱试验评估它们的神经毒性。使用福尔马林对神经源性疼痛的测试评估了表现出最有益活性和保护指数的化合物的镇痛活性。还使用体外评估了它们对细胞毒活性的影响细胞模型(HepG2 和 CRL-2534 细胞系)。使用 MTT 和中性红细胞毒性测定进行的实验表明,所有评估的化合物对正常的神经胶质细胞(星形胶质细胞)都是安全的,并且不会引起肝毒性作用。根据体外研究的结果,推断出所评估化合物的安全性。本研究中最有希望的化合物是 1-{2-[2-(2,3-二甲基苯氧基)乙氧基]乙基}哌啶-3-醇盐酸盐。此外,已经对该化合物进行了计算机代谢预测。
    DOI:
    10.1039/c6md00537c
  • 作为产物:
    描述:
    2-[2-(2,4-Dimethylphenoxy)ethoxy]oxane甲醇4-甲基苯磺酸吡啶 作用下, 以 甲醇 为溶剂, 反应 16.0h, 以99%的产率得到2-(二甲基苯氧基)乙醇
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of Aryloxyethyl Thiocyanate Derivatives against Trypanosoma cruzi
    摘要:
    As a continuation of our project aimed at the search for new and safe chemotherapeutic and chemoprophylactic agents against American trypanosomiasis (Chagas' disease), several drugs structurally related to 4-phenoxyphenoxyethyl thiocyanate (4) were designed, synthesized, and evaluated as antiproliferative agents against the parasite responsible for this disease, the hemoflagellated protozoan Trypanosoma cruzi. This thiocyanate derivative was previously shown to be an effective and potent agent against T. cruzi proliferation. Several drugs possessing thiocyanate groups proved to be effective growth inhibitors of T. cruzi growth. Among the designed compounds, it is important to point out the extremely potent activity shown by 11, 23, 38, 53, 90, 99, and 117 against the epimastigote forms of the parasite. All of them exhibited IC50 values in the low micromolar range, and these values were comparable with those presented by our lead drug 4 and ketokonazole, a well-known antiparasitic agent. The activity displayed by the nitrogen-containing derivative 90 was very promising with IC50 values of 3.3 muM. Several other thiocyanate derivatives also proved to be very potent inhibitors of the multiplication of T. cruzi epimastigotes, such as compounds 28, 33, 43, 48, 56, 61, 66, 71, 76, and 124. Compound 43 resulted in being a promising drug because it was also very effective against amastigotes, the clinically more relevant form of the parasite. This compound was Mold more potent than 4, while 11 showed nearly the same activity as our lead drug against intracellular T. cruzi. It was very surprising that the experimental juvenoid 124, although fairly devoid of activity against epimastigotes, was very effective against intracellular amastigotes growing in myoblasts. The rest of the designed compounds showed a broad degree of inhibitory action, from moderately active drugs to drugs almost devoid of antiparasitic activity. Compound 43 is an interesting example of an effective antichagasic agent that presents excellent prospectives not only as a lead drug but also to be used for further in vivo studies.
    DOI:
    10.1021/jm0201518
点击查看最新优质反应信息

文献信息

  • [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS<br/>[FR] DERIVES DE NICOTINAMIDE UTILES EN TANT QU'INHIBITEURS DE PDE4
    申请人:PFIZER LTD
    公开号:WO2005009965A1
    公开(公告)日:2005-02-03
    This invention relates to nicotinamide derivative of general formula (I), in which R1, R2 and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.
    这项发明涉及一般式(I)的烟酰胺衍生物,其中R1、R2和R3具有本文中定义的含义,以及含有这些衍生物并将其用作PDE4抑制剂的组合物。
  • PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
    申请人:Hadida Ruah Sara Sabina
    公开号:US20120196869A1
    公开(公告)日:2012-08-02
    The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    这项发明涉及对离子通道具有抑制作用的吡咯吡嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物,以及使用这些组合物治疗各种疾病的方法。
  • [EN] PROTEIN KINASE C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE KINASE C ET UTILISATIONS DE CEUX-CI
    申请人:RIGEL PHARMACEUTICALS INC
    公开号:WO2013152198A1
    公开(公告)日:2013-10-10
    This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    这份披露涉及一些化合物,这些化合物可用作蛋白激酶C(PKC)的抑制剂,因此可用于治疗通过PKC的活性介导或维持的各种疾病和紊乱。这份披露还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和紊乱的方法,制备这些化合物的过程以及在这些过程中有用的中间体。
  • [EN] MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE PIPÉRIDINE SPIROCYCLIQUES MORPHOLINES UTILISÉS EN TANT QUE MODULATEURS DE CANAUX IONIQUES
    申请人:VERTEX PHARMA
    公开号:WO2012125613A1
    公开(公告)日:2012-09-20
    The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    这项发明涉及吗啡啶螺环哌啶酰胺化合物,可用作离子通道抑制剂。该发明还提供了包括该发明化合物的药用可接受组合物,以及使用这些组合物治疗各种疾病的方法。
  • Chemoselective<i>O</i>-formyl and<i>O</i>-acyl protection of alkanolamines, phenoxyethanols and alcohols catalyzed by nickel(<scp>ii</scp>) and copper(<scp>ii</scp>)-catalysts
    作者:Rahul B. Sonawane、Swapnali R. Sonawane、Nishant K. Rasal、Sangeeta V. Jagtap
    DOI:10.1039/d0gc00520g
    日期:——
    alkanolamines, that have both amines and alcohols as reactive functional groups. Achieving 100% selectivity for O-formyl and O-acyl protection of alkanolamines is one of the examples of such reactions. To avoid protection and deprotection steps and overcome this problem, a novel chemoselective, efficient, and simple protocol for functional group protection as O-formylation and O-acylation of alkanolamines and
    对于具有胺和醇作为反应性官能团的双官能化合物(例如烷醇胺),实现化学选择性始终是至关重要且具有挑战性的。这种反应的例子之一是使烷醇胺的O-甲酰基和O-酰基保护的选择性达到100%。为避免保护和脱保护步骤并克服这一问题,Ni(Ni(Ni))催化了一种新的化学选择性,有效且简单的官能团保护方案,如烷醇胺和苯氧基乙醇的O-甲酰化和O-酰化以及醇和胺之间的竞争性O-选择性。II)和Cu(II)在均相介质中仅以5 mol%的催化剂负载量与8-羟基喹啉形成络合物。在不存在用于室温下以甲酸为甲酰基源的O-甲酰化溶剂和在70°C下以乙酸为酰基源的O-酰化条件下,可获得良好或优异的收率。另外,在该反应过程中产生最少的废水和废物,因为相应的酸的钠盐可以在该过程中回收并可以重复使用。这种化学反应容易耐受各种官能团,如20个对烷醇胺的O-甲酰化和O-酰化具有100%化学选择性的实例以及30个O-甲酰化和在已成功合
查看更多